Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

La Jolla Pulls Riquent EU Marketing Application Due To Clinical Data Needs

This article was originally published in The Pink Sheet Daily

Executive Summary

Lupus renal disease treatment is still “approvable” in the U.S. pending submission of additional data to FDA.

You may also be interested in...



La Jolla Submits Riquent Application For Lupus In EU

The company is still pursuing a Phase III trial in the U.S. under a Special Protocol Assessment with FDA.

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.

MADIT-CRT Data Support Expanded Cardiac Resynchronization Market

The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel